Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.
New analyses from the DELTA FORCE and DELTA TEEN programmes extend the chronic hand eczema discussion beyond skin clearance. The findings could strengthen the clinical and economic case for delgocitinib, although real-world effectiveness, adolescent regulation and treatment access remain important tests.
Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.
Natera’s Prospera assay will provide serial molecular graft surveillance in Eledon’s planned Phase 3 tegoprubart study, creating a major test of how diagnostics can strengthen transplant drug development.
The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.
The Dual Energy THERMOCOOL SMARTTOUCH SF Platform gives electrophysiologists pulsed field and radiofrequency ablation through one catheter, expanding procedural flexibility while raising new questions about evidence, efficiency and adoption.
The decision gives clinicians a Trodelvy-based option for patients who cannot receive checkpoint inhibitors and a Trodelvy plus Keytruda regimen for PD-L1-positive disease. The immediate clinical impact is substantial, although immature overall-survival data, toxicity management and treatment cost will influence how rapidly the new pathways displace chemotherapy.
Tryngolza is no longer confined to the rare familial chylomicronemia syndrome market. Its broader United States approval gives clinicians the first therapy specifically shown to reduce acute pancreatitis risk in adults with severe hypertriglyceridemia, although questions surrounding dose selection, hepatic monitoring, reimbursement and long-term use will influence how quickly the treatment changes practice.
The FDA approval brings CDK4/6 inhibition into HR-positive, HER2-positive metastatic breast cancer maintenance, although toxicity, immature survival data and a rapidly changing first-line market could shape adoption.
The legal fight over Kadima Neuropsychiatry Institute tests NRx Pharmaceuticals’ acquisition discipline, financing credibility and evolving interventional psychiatry strategy.